Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. (30th December 2013)

• Record Type: Journal Article
• Authors: Johansson, Isabelle; Edner, Magnus; Dahlström, Ulf; Näsman, Per; Rydén, Lars; Norhammar, Anna
• Is Part Of: European journal of heart failure. Volume 16:Number 4(2014)
• Page Start: 409
• Page End: 418
• Publication Date: 2013-12-30
• Subjects: Heart failure -- Diabetes -- Mortality -- Revascularization -- Registry; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.44
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract : Aims: To analyse the long‐term outcome, risk factor panorama, and treatment pattern in patients with heart failure (HF) with and without type 2 diabetes (T2DM) from a daily healthcare perspective. Methods and results: Patients with ( n = 8809) and without ( n = 27 465) T2DM included in the Swedish Heart Failure Registry (S‐HFR) 2003–2011 due to a physician‐based HF diagnosis were prospectively followed for long‐term mortality (median follow‐up time: 1.9 years, range 0–8.7 years). Left ventricular function expressed as EF did not differ between patients with and without T2DM. Survival was significantly shorter in patients with T2DM, who had a median survival time of 3.5 years compared with 4.6 years ( P < 0.0001). In subjects with T2DM. unadjusted and adjusted odds ratios (ORs) for mortality were 1.37 [95% confidence interval (CI) 1.30–1.44) and 1.60 (95% CI 1.50–1.71), and T2DM predicted mortality in all age groups. Ischaemic heart disease was an important predictor for mortality (OR 1.68, 95% CI 1.47–1.94), more abundant in patients with T2DM (59% vs. 45%) among whom only 35% had been subjected to coronary angiography and 32% to revascularization. Evidence‐based pharmacological HF treatment was somewhat more extensive in patients with T2DM. Conclusion: The combination of T2DM and HF seriously compromises long‐term prognosis. Ischaemic heart disease was identified as one major contributor; however, underutilization of available diagnostic and therapeutic facilities for ischaemic heart disease was obvious and may be an important area for future improvement in patients with T2DM and HF.